GENMAB A/S Genmab A/S Share Price Deutsche Boerse AG
Equities
GE9
DK0010272202
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 243.6 EUR | -0.25% |
|
-5.95% | -15.24% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 19.81B 2.84B 2.65B 224B | Sales 2025 * | 23.61B 3.39B 3.16B 267B | Capitalization | 118B 16.89B 15.76B 1,331B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.67B 670M 626M 52.84B | Net income 2025 * | 6.54B 938M 875M 73.93B | EV / Sales 2024 * | 4.63 x |
| Net cash position 2024 * | 25.89B 3.71B 3.47B 293B | Net cash position 2025 * | 32.22B 4.62B 4.31B 364B | EV / Sales 2025 * | 3.62 x |
| P/E ratio 2024 * |
27
x | P/E ratio 2025 * |
19.6
x | Employees | 2,286 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab A/S
More recommendations
More press releases
More news
| 1 day | -0.25% | ||
| 1 week | -5.95% | ||
| Current month | -5.69% | ||
| 1 month | -9.71% | ||
| 3 months | -11.90% | ||
| 6 months | -16.20% | ||
| Current year | -15.24% |
1 week
243.60
256.60
1 month
243.60277.90
Current year
243.60296.50
1 year
243.60372.00
3 years
243.60445.10
5 years
145.00445.10
10 years
27.55445.10
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/12/98 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 31/12/06 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 22/03/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 31/12/16 |
| Director/Board Member | 73 | 31/10/03 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 31/12/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/06/24 | 243.6 | -0.25% | 21 |
| 13/06/24 | 244.2 | -0.57% | 1 |
| 12/06/24 | 245.6 | -2.54% | 1 |
| 11/06/24 | 252 | -1.79% | 9 |
| 10/06/24 | 256.6 | -0.93% | 10 |
Delayed Quote Deutsche Boerse AG, June 14, 2024 at 08:50 pm
More quotes
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,832
DKK
Average target price
2,464
DKK
Spread / Average Target
+34.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.15% | 124B | |
| +18.02% | 112B | |
| -12.75% | 22.22B | |
| +5.07% | 22.94B | |
| -39.94% | 16.87B | |
| -9.86% | 17.02B | |
| +2.80% | 13.63B | |
| +27.39% | 11.61B | |
| +106.26% | 10.31B |
- Stock Market
- Equities
- GMAB Stock
- GE9 Stock
